TurnerTrends Stock Rating Report for CGEN
Data valid for week beginning August 25, 2008
|
CGEN [News]
|
Compugen Ltd
|
Company Profile
"Compugen, Ltd. engages in the discovery, validation, and commercialization of therapeutic and diagnostic biomarker products for cancer, cardiovascular, and immune-related diseases in North America and Europe. Its products are developed based on computer-based discovery platforms, as well as by analyzing various biological data, such as DNA or RNA sequences, gene expression data, protein network data, and data related to drugs in development and to drugs already being commercialized. The company's validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, and Disease-Associated Conformation Blocker. Its therapeutic product candidates include CGEN-54, a splice variant of the MCP-1 chemokine for inflammatory conditions and cancer- CGEN-241, a splice variant of the MET receptor- CGEN-34, a splice variant of the peptide ANP for cardiovascular system- CGEN-855, an FPRL1 GPCR peptide agonist that consists anti-inflammatory properties- and CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists that have cardiovascular therapeutic properties. Compugen also focuses on the development of traits in plants through gene discovery, genome remodeling, and advanced classical breeding techniques. The company has collaboration and license agreements with Roche- Siemens Healthcare Diagnostics, Inc.- Ortho-Clinical Diagnostics- Biosite- and Teva Pharmacuetical Industries, Ltd.- Merck & Co.- Teva Pharmaceutical Industries, Ltd.- and Medarex, Inc. Compugen was founded in 1993 and is headquartered in Tel Aviv, Israel."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Thu, 28 Aug 2008 12:00:00 Etc/GMT | Monsanto and Evogene Collaborate on Yield and Stress Research (Marketwire) | | Thu, 14 Aug 2008 13:21:00 Etc/GMT | Evogene Reports Second Quarter 2008 Financial Results (Marketwire) | | Tue, 29 Jul 2008 18:20:00 Etc/GMT | Israel Stocks: CORRECT: Market's mixed; Teva beats estimate and shares decline (at MarketWatch) | | Tue, 29 Jul 2008 14:00:00 Etc/GMT | Compugen Earnings Call scheduled for 10:00 am ET today (CCBN) | | Tue, 29 Jul 2008 11:07:13 Etc/GMT | Q2 2008 Compugen Earnings Release - Time Not Supplied (CCBN) | | Tue, 29 Jul 2008 11:00:00 Etc/GMT | Compugen Reports Second Quarter 2008 Results (Business Wire) | | Tue, 22 Jul 2008 11:00:00 Etc/GMT | Compugen Ltd. to Review Second Quarter 2008 Results on Tuesday, July 29, 2008 (Business Wire) | | Wed, 16 Jul 2008 11:00:00 Etc/GMT | Compugen Planning Proof of Concept Human Trial for Breast Cancer Drug Candidate in 2009 (Business Wire) | | Wed, 9 Jul 2008 11:00:00 Etc/GMT | Compugen Announces Positive In-Vivo Results for Therapeutic Peptide Candidate for Immune Related Diseases (Business Wire) | | Thu, 26 Jun 2008 11:00:00 Etc/GMT | Compugen Announces Discovery of Biomarkers for Early Pre-Clinical Detection of Drug-Induced Kidney Toxicity (Business Wire) | | Wed, 11 Jun 2008 12:56:00 Etc/GMT | Israel Stocks: Teva rebounds from Copaxone-rival report; Alvarion, Nortel team (at MarketWatch) | | Wed, 11 Jun 2008 11:00:00 Etc/GMT | Compugen Announces Discovery of Novel Drug Targets for Cancer Antibody Therapeutics (Business Wire) | | Wed, 28 May 2008 14:00:00 Etc/GMT | Evogene to Collaborate With Vilmorin for Tomato Yield Improvement (Marketwire) | | Wed, 21 May 2008 13:20:00 Etc/GMT | Evogene Reports First Quarter 2008 Financial Results (Marketwire) | | Wed, 14 May 2008 14:00:00 Etc/GMT | Compugen Earnings Call scheduled for 10:00 am ET today (CCBN) | | Wed, 30 Apr 2008 14:00:00 Etc/GMT | Thanks Evogene Announces $2,000,000 Private Investment by AquAgro Venture Fund (Marketwire) | | Wed, 23 Apr 2008 13:04:22 Etc/GMT | COMPUGEN LTD Financials (EDGAR Online Financials) | | Thu, 13 Mar 2008 13:30:00 Etc/GMT | Evogene Reports Fourth Quarter and Annual 2007 Results (Marketwire) | | Wed, 13 Feb 2008 15:00:00 Etc/GMT | Viterra and Evogene to Develop Canola With Improved Yield and Stress Tolerance Traits (Marketwire) | | Wed, 19 Dec 2007 14:00:00 Etc/GMT | Successful Third Year Field Trial of Evogene's Candidate Gene for Improving Yield and Abiotic Stress Tolerance (Marketwire) | News provided by Yahoo! Finance |
|
